Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1079-1082

  Rogers, Janyce F ^a   Nafziger, Anne N ^a,b   Kashuba, Angela D M ^c   Streetman, Daniel S ^d   Rocci Jr , Mario L ^e   Choo, Edna F ^f   Wilkinson, Grant R ^f   Bertino Jr , Joseph S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b University of North Carolina ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Oneida Research Services Inc   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; LIVER TRANSPLANTATION; MALE; VALIDATION PROCESS;

ADULT; AGED; AREA UNDER CURVE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MULTICENTER STUDIES;

EID: 0036784471     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382614     Document Type: Article

References (12)

1. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, et al: Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail." Clin Pharmacol Ther 2000;68:375-383.
2. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
3. Streetman DS, Bertino JS Jr, Nafziger AN: Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216.
4. Kashuba AD, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN: Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998;64:269-277.
5. Kim JS, Nafziger AN, Tsunoda SM, Choo EF, Streetman DS, Kashuba AD, et al: Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 2002;42:376-382.
6. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
7. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
8. Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S: Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. J Clin Pharmacol 2001;41:305-316.
9. Kim JS, Nafziger AN, Tsunoda SM, Choo EF, Streetman DS, Kashuba AD, et al: Validation of a minimized plasma sampling strategy (MPSS) to calculate AUC of the CYP3A probe midazolam (MID). Clin Pharmacol Ther 2000;67:161.
10. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R: Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000;119:670-676.
11. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-551.
12. MICROMEDEX® Healthcare Series. MICROMEDEX. Greenwood Village, CO (edition expires 6/2002).